Former President and Chief Executive Officer · Arbutus Biopharma Corp (ABUS)

William Collier

A named executive officer of Arbutus Biopharma in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$3,385,984

Salary $637,100Stock awards $627,850

FY2022: $2,645,657

1st of 5 named executive officers at Arbutus Biopharma by FY2023 total.

5 named officers on file for Arbutus Biopharma, FY2023

William Collier’s pay file — $29

  • 5 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Arbutus Biopharma’s whole pay program stands against its peers

  • Arbutus Biopharma’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ABUS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 10, 2024 (DEF 14A).

Free

Get William Collier’s full pay file as a PDF — free

More than this page: up to 10 years of William’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

William Collier compensation by year

Arbutus Biopharma Summary Compensation Table · all 5 fiscal years held
In US dollars, as Arbutus Biopharma reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023
Salary$285,577$566,500$583,500$606,800$637,100
Bonus$100,000$0$0$0$0
Stock awards$0$0$0$0$627,850
Option awards$1,792,048$1,756,007$2,185,473$1,712,646$1,897,476
Non-equity incentive$150,945$395,842$436,166$315,536$0
Pension and deferred compensation$0$0$0$0$0
All other$5,615$9,975$10,150$10,675$223,558
Total$2,334,185$2,728,324$3,215,289$2,645,657$3,385,984

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arbutus Biopharma Corp DEF 14A filed April 10, 2024, accession 0001140361-24-019091, and prior-year filings.

How this page was built: the Arbutus Biopharma Corp filed document, accession 0001140361-24-019091. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2024.

$2.3M
$2.7M
$3.2M
$2.6M
$3.4M
FY19
FY20
FY21
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU216,500$541,250—
Option10,930—$3.35
Option196,875—$4.33
Option15,295—$3.35
Option410,182—$2.81
Option685,583—$2.90

Per the Outstanding Equity Awards at Fiscal Year-End table in Arbutus Biopharma Corp's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Arbutus Biopharma’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
William Collier · this pageFormer President and Chief Executive Officer$3,385,984
Elizabeth HowardFormer Executive Vice President, General Counsel, Chief Compliance Officer and Secretary$1,842,723
Michael McElhaughCurrent Interim President and Chief Executive Officer$1,620,485
Michael SofiaFormer Chief Scientific Officer$1,614,688
David HastingsFormer Chief Financial Officer$1,556,806

The full Arbutus Biopharma compensation record

free company brief

This page is one person within Arbutus Biopharma's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arbutus Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

William Collier's compensation dossier · One-time report. No refunds.